手术治疗前子宫平滑肌瘤替代性瑞格列克给药方案的临床试验:非不良事件瑞格列克给药(NARA)试验研究方案
本研究为最小化自适应随机对照试验,纳入20岁以上将接受手术的子宫平滑肌瘤患者,比较每日给药24周与每日给药8周后隔日给药16周的方案。主要结局为肌瘤体积缩小,次要结局包括子宫体积缩小、更年期障碍发生、出血天数、血清激素及骨转换标志物变化率和骨密度。目标是证明隔日给药在肌瘤缩小上非劣效且不良反应发生更优。
要点
- 隔日给药方案旨在维持肌瘤缩小效果的同时减少不良反应。
- 主要结局为治疗24周后肌瘤体积缩小,需证明非劣效。
- 次要结局包括更年期障碍、出血天数、激素与骨转换标志物及骨密度。
核心结论
- 本试验旨在证明每日给药8周后隔日给药16周在肌瘤体积缩小上非劣效于每日给药24周,并在不良反应发生减少上更优。
研究设计与样本
- 最小化自适应随机对照试验,纳入20岁以上将接受手术的子宫平滑肌瘤患者。
- 干预组每日给药8周后隔日给药16周,对照组每日给药24周。
主要发现
- 瑞格列克(40 mg口服每日一次)作为促性腺激素释放激素受体拮抗剂,与促性腺激素释放激素激动剂相比,能充分抑制雌二醇水平且无暂时性雌二醇 flare-up。
- 长期给药可能因更年期障碍或骨质疏松而不被允许,隔日给药方案的实际疗效和不良反应程度缺乏证据。
关键数值与推荐
- 主要结局为治疗24周后肌瘤体积缩小。
- 次要结局包括子宫体积缩小、更年期障碍发生、生殖道出血天数、血清激素或骨转换标志物变化率及骨密度(与给药前比较)。
局限性
- 隔日给药方案的实际疗效和不良反应程度缺乏证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine leiomyomas are common for reproductive-aged women and affect women's quality of life due to heavy menstrual bleeding or dysmenorrhea. Leiomyomas grow according to estradiol exposure and decrease after post-menopause. In case serious symptoms are caused by leiomyomas, pharmacotherapy or surgical treatment is proposed. Prior to surgical treatment, pharmacotherapies aimed at the reduction of leiomyoma and uterine volume or improvement of anemia are introduced to conduct minimum invasive surgery (i.e., to reduce blood loss or surgical duration). Recently, relugolix (40 mg orally once daily) as a gonadotropin-releasing hormone (GnRH) receptor antagonist has proved its sufficient efficacy in suppressing estradiol levels without the transient estradiol flare-up compared with GnRH agonist. However, long-term administration should not be permitted liable to for climacteric disorder or osteoporosis, and evidence is lacking on the actual efficacy and extent of adverse effects of the every-other-day dosing regimen. This trial aimed to prove non-inferiority in volume reduction effect on leiomyoma and safety (i.e., reduction of adverse effects) by every-other-day administration after 2 months of everyday administration compared to daily administration throughout the duration. METHODS: A minimization adaptive randomized control trial (RCT) will be conducted. Patients (over 20 years old) harboring leiomyoma who will be undergoing surgical treatment will be invited to participate. Patients who are enrolled in the intervention group will receive every-other-day administration for 16 weeks after 8 weeks of daily administration. Patients who are enrolled in the control group will receive daily throughout the 24 weeks. The primary outcome is the leiomyoma volume reduction, and the secondary endpoints are the reduction of uterine volume, the occurrence of the climacteric disorder, genital bleeding days, change rate of serum hormone or bone turnover markers, and bone mineral density after 24 weeks compared to before administration. DISCUSSION: This study aims to prove both the non-inferiority in leiomyoma volume reduction and superiority in adverse effects occurrence reduction, which will provide a novel method to escape adverse effects while maintaining the effect of leiomyoma reduction. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051230078. Registered on 26 July 2023.
引用
- Kawahara N, Kawaguchi R, Yamamoto K, et al. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial. Trials. 2024. PMID: 38243317. doi:10.1186/s13063-024-07923-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。